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ECONOMIC EVALUATION OF VILDAGLIPTIN AS ADD-ON THERAPY TO
METFORMIN IN DIABETES MELLITUS TREATMENT IN CHINA
Chen W1, Zhu J2
1Fudan University, Shanghai, Shanghai, China, 2Fudan University, Shanghai, China
OBJECTIVES: To evaluate the cost effectiveness of vildagliptin compared to pioglita-
zone and glimepiridewhen added on tometformin in the treatment of type 2 diabetes
mellitus inChina.METHODS:AMarkovmodelwasdesigned to evaluate the costs and
outcomes (life years and QALYs gained) of three different therapies of diabetesmelli-
tus from health insurance perspective. Based on UKPDS Outcomes Model, the model
included the following riskengine tosimulatecomplications, including ischemicheart
disease, fatal and non-fatal myocardial infarction, heart failure, stroke, blindness,
renal failure, amputation, diabetes-related mortality and other deaths. The clinical
and quality of life data were obtained from published literature and re-confirmed
based on a questionnaire survey froma clinical expert panel of 20 diabetes specialists.
The annual cost was calculated based on expert opinions. A probabilistic sensitivity
analysis was performed to understand the key drivers and general sensitivity of the
model. RESULTS: The results showed that compared to the treatment of
metforminpioglitazone and metforminglimepiride therapy, the add-on of vilda-
gliptin canprovide a gain of 0.07 and 0.13QALYsper patient, respectively. The lifetime
cost per patient treated with vildagliptin, pioglitazone and glimepiride added-on to
metformin was CNY 124,892 (US$19,824), CNY 134,135 (US$21,291) and CNY 126,010
(US$20,002), respectively.CONCLUSIONS: Compared tometforminpioglitazone and
metforminglimepiride therapies, vildagliptin add-on to metformin therapy im-
proves health outcomes and also leads to cost saving in the treatment of diabetes
mellitus in China.
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COST-EFFECTIVENESS MODELLING OF TYPE-1 DIABETES
Thokala P
University of Sheffield, Sheffield, UK
OBJECTIVES: To build a flexible and comprehensive long term Type-1 diabetes
model incorporating themost up-to-date methodologies (e.g. capturing parameter
uncertainty, timeprofile of patient characteristics and including patient behaviour)
to allow a number of cost-effectiveness evaluations.METHODS: An individual pa-
tient level discrete event simulationmodel which includes all the major complica-
tions (nephropathy, neuropathy, retinopathy, CVD, PVD, hypoglycaemia, ketoaci-
dosis) and their interactions along with the treatment effects was built based on
the developed conceptual model. Patient characteristics (demographics, clinical
variables, existing complications and treatment status) are used to estimate the
transition probabilities for different eventswithHbA1c acting as the key variable in
themodel. Patient behaviourwas also incorporated in the cost-effectivenessmodel
by updating HbA1c and other variables in time based on the patient’s behaviour.
The model was developed in a flexible manner to allow alternative sets of risk
equations to be used and themodel is being validated for each set of risk equations.
Furthermore, the model is capable of performing probabilistic sensitivity analysis
allowing us to capture the effects of parameter uncertainty and report the likeli-
hood that interventions are cost-effective. RESULTS: A number of cost-effective
analyses were performed and the trade-offs between costs and QALYs are pre-
sented for different treatment/interventions. CONCLUSIONS: The flexible individ-
ual patient level discrete event simulationmodel developed enables cost-effective-
ness evaluations of a number of treatments and interventions for Type-1 diabetes.
The model allows tracking the history of each of the patients and this enables
identification of different sub-groups for targeted interventions. Sensitivity analy-
sis, probabilistic sensitivity analysis and value of informationmethodswill be used
to identify the most important parameters in the model.
DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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THE PREVALENCE AND BURDEN OF COMORBID HYPERTENSION AND OBESITY
AMONG PATIENTS WITH TYPE 2 DIABETES IN JAPAN
DiBonaventura MD1, Fukuda T2, Stankus A3
1Kantar Health, New York, NY, USA, 2National Institute of Public Health, Saitama, Japan,
3Kantar Health, Princeton, NJ, USA
OBJECTIVES: Although hypertension and obesity are common comorbidities among
patients with type 2 diabetes (T2D), their prevalence and burden has often not been
explored outside the US. The objective of the current study was to assess the incre-
mental effect of eachcomorbidity in isolationand in combinationamongT2Dpatients
in Japan.METHODS: Data from the 2010 Japan National Health andWellness Survey
(NHWS) were used in the analysis. The NHWS is an Internet-based self-reported sur-
vey administered to the adult population of Japan (N25,000). Respondents who re-
ported a diagnosis of T2D and provided weight information were included in the
analysis; they were subsequently categorized based on their comorbidities:
T2Dobesityonly,T2Dhypertensiononly,T2Dobesityhypertension,orT2Dwith-
out either obesity or hypertension. Groupswere compared on health status (using the
SF-12v2) and self-reported health care resource use in the past six months through
regression modeling controlling for demographics, health behaviors, and
comorbidities. RESULTS: Of the 957 patients who reported a diagnosis of T2D, most
reported neither an obesity nor hypertension comorbidity (n506; 52.87%). 255
(26.65%) patients reported T2Dhypertension, 98 (10.24%) reported T2Dobesity, and
98 (10.24%) reported both T2Dhypertensionobesity. Adjusting for demographics,
health behaviors, and comorbidities, patients with T2Dobesity (Mean43.42),
T2Dhypertension (Mean46.51), and T2Dobesityhypertension (Mean44.03) all
reported significantly worse physical component summary scores than those with
only T2D (Mean47.76) (p.05). Similar, though slightly weaker, differences were ob-
served with respect to health utilities. All comorbidity groups also reported signifi-
cantly more physician visits (T2Dobesity14.25; T2Dhypertension12.06;
T2Dhypertensionobesity15.37) in the past sixmonths comparedwith thosewith
only T2D (9.94; all ps.05).CONCLUSIONS:Althoughmost patients in Japanwith T2D
do not have concomitant hypertension or obesity, those that do report a significant
health status and direct cost burden. Improved management of these comorbidities
could result in a substantial societal benefit.
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THE PREVALENCE AND BURDEN OF COMORBID HYPERTENSION AND OBESITY
AMONG PATIENTS WITH TYPE 2 DIABETES IN URBAN CHINA
DiBonaventura MD1, Liu GG2, Stankus A3
1Kantar Health, New York, NY, USA, 2Peking University, Beijing, China, 3Kantar Health,
Princeton, NJ, USA
OBJECTIVES: Past research has shown strong associations of hypertension and obe-
sitywith type2diabetes (T2D); however,most of these studieshavebeenconducted in
the US. Given that 92million patients in China currently have diabetes, the aim of the
current study was to assess the prevalence and burden associated with these two
comorbidities.METHODS: The data source for the current study was the 2010 China
National Health and Wellness Survey (NHWS). The NHWS is a self-reported survey
administered to the adult population of urban China using a mixed methodology
(N19,954). Only respondents who reported that they had been diagnosed with T2D,
and who provided weight information, were included in the analysis. Those with
T2Dhypertension only, T2Dobesity only, and T2Dobesityhypertension were
compared with T2D only patients on health status (using the SF-12v2) and self-re-
ported health care resource use in the past six months. Regression modeling con-
trolled for demographics, health behaviors, and comorbidities. RESULTS: A total of
552 patients reported a diagnosis of type 2 diabetes with 148 (26.81%) reporting con-
comitant hypertension, 52 (9.42%) being obese, 43 (7.79%) reporting hypertension and
being obese, and 309 (55.98%) having neither comorbidity. Adjusting for demograph-
ics, health behaviors, and comorbidities, patients with T2Dhypertension
(Mean42.25), T2Dobesity (Mean42.29) and T2Dobesityhypertension
(Mean40.99) all reported significantly worse physical component summary scores
than those with only T2D (Mean44.80) (p.05). All comorbidity groups also reported
significantly worse health utilities (T2Dhypertension0.67; T2Dobesity0.67;
T2Dhypertensionobesity0.67) compared with those with only T2D (0.71). Similar
significant effects were observed for the number of provider visits, emergency room
visits, and hospitalizations. CONCLUSIONS: Although most patients in urban China
with T2D do not have concomitant hypertension or obesity, those that do report a
significant health status and direct cost burden. Improved management of T2D and
these comorbidities could result in a large societal benefit.
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OUTCOMES AND PERCEPTIONS OF 4MM PEN NEEDLE USE IN DIABETES
PATIENTS: RESULTS FROM A MULTI-CENTER SURVEY PILOT STUDY IN HONG
KONG
Mok PH1, Cheng MW2
1United Christian Hospital, Hospital Authority, HONG KONG, Hong Kong, 2Queen Elizabeth
Hospital, Hospital Authority, HONG KONG, Hong Kong
OBJECTIVES: A recent study showed that 4mm pen needle (PN) has significantly
lowered risk of intramuscular insulin injection and thus reduced risk of hypogly-
cemia. It is important, however, to understand whether diabetes patients are well
adapted to 4mm PN when switched from longer needles. The study is to evaluate
the difference in patient perception and outcomes before and after switching to the
new 4mm PN. METHODS: A prospective pilot survey study was conducted from
August 2011 to March 2012 in two public hospitals in Hong Kong. Thirty-four sub-
jects with diabetes on longer PN (8mm, 6mm or 5mm) were randomly selected and
consented to switch to 4mm PN for two to four weeks. Questionnaires included
perception and outcomes Five-point Likert scales were employed to measure pain
level, satisfaction level, insulin leakage, injection pressure, and ease of injection to
different body areas pre- and post- switch of longer to shorter PN. Insulin leakage
volume pre- and post switch was compared using a droplet size chart representing
1uL, 10uL, 20uL, and 40uL. Statistical analyses were conducted using SAS (v9.1).
RESULTS: The overall response rate was 94.1% (N32). Demographics of respon-
dents: 48.918.6 years (13-76 years); 64.5% females; 46.7% T1DM; A1C: 8.71.7%
(5.7-12.7%); BMI: 24.045.1kg/ m2 (17.5-40.0kg/m2); average insulin dosage:
46.918.6U (6-86U). Of all analyzed, 33.3% generally injected with high speed to
avoid pain. There was no significant difference in the volume of insulin leakage
pre- and post PN switch when injecting on abdomen (p 0.7530) or thigh
(p0.5637); no significant difference in level of pain (p0.0519). CONCLUSIONS:
The use of 4mm PN showed no difference in outcomes and perception of use when
switched from 8, 6, 5 mm PN in a heterogeneous sample with obese, overweight,
normal and skinny patients. A tendency of preference towards 4mmPNwith lower
pain level and less leakage may be observed with larger sample size.
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PHYSICIAN’S AND PATIENT’S PERCEPTIONS AND BELIEFS REGARDING INSULIN
INITIATION AND USE IN PATIENTS WITH TYPE 2 DIABETES (T2DM) IN CHINA
Liu LL1, Babineaux SM2, Kadziola Z3, Brnabic AJ4, Luo T1
1Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China, 2Eli Lilly & Co., Dublin, OH, USA, 3Eli
Lilly GmbH, Vienna, Austria, 4Eli Lilly Australia Pty. Ltd., Sydney, Australia
OBJECTIVES: To explore physician’s and patient’s perceptions of insulin initiation
and use in patients with T2DM in China. METHODS: This study used the 2008
Adelphi T2DM Disease Specific Programme©, a cross-sectional study of consulting
physicians and patients providing insights into ‘real-world’ behaviours and atti-
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tudes in clinical practice. Data was collected on 1648 patients with T2DM receiving
at least one oral anti-diabetic with/without insulin and 141 specialists and 59 in-
ternal medicine physicians in 9 Chinese cities, through physician interviews, pa-
tient record forms, and self-completed questionnaires. RESULTS: Among the 200
physicians in the study, the most frequently reported concerns with starting insu-
lin were patient’s acceptance and ability to comply in the long-term (91.9% of
respondents), and the long timeneeded to train on injection techniques and dosing
(74.0%). Forty-three percent of physicians believe patients fear injections, but a
higher percentage of patients (55.3%) report not liking injections. Thirty-seven per-
cent of physicians believe social stigma is a barrier; only about 17.1% of insulin-
naive patients believe so. Among 474 insulin-naive patients, the most frequently
reported concern was that starting insulin would mean their diabetes is at an
advanced stage (67.5% of respondents). Physicians underestimate that concern,
with only 30% reporting that as a barrier. Almost half of insulin-naive patients
(45.1%) would consider insulin initiation as a personal failure to control their dia-
betes. Among 346 patients taking insulin, 60.1% reported feeling better and 55.7%
felt amore positive outlook since starting insulin; 59.8% thought insulinmade their
diabetes easier tomanage. CONCLUSIONS: Physicians in Chinamay over or under-
estimate patient perceived barriers to, and satisfaction with, insulin initiation.
Physician/patient education focused on perceived barriers to insulin initiation, and
patient/physician communication may facilitate the initiation of insulin in pa-
tientswith this progressive disease. Interventions to address system-level barriers,
e.g. time for training, are warranted.
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IMPROVEMENTS IN QUALITY OF LIFE ASSOCIATED WITH BIPHASIC INSULIN
ASPART 30 IN TYPE 2 DIABETES PATIENTS IN CHINA: RESULTS FROM THE
A1CHIEVE OBSERVATIONAL STUDY
Yang WY1, Shi YQ2, Li YK3, Wang Y4, Li YX5
1China-Japan Friendship Hospital, Beijing, China, 2Shanghai Changzheng Hospital, Shanghai,
China, 3The Third Hospital of Hebei Medical University, Shijiazhuang, China, 4Novo Nordisk
(China) Pharmaceuticals Co., Ltd., Beijing, China, 5Peking Union Medical College Hospital, Beijing,
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OBJECTIVES: To examine the effects on the health-related quality of life (HRQoL)
after starting insulin with, or switching to, biphasic insulin aspart 30 (BIAsp30) in
Chinese subjects with type 2 diabetes (T2DM) in the A1chieve study. METHODS:
The A1chieve study was a 24-week, prospective, non-interventional, observational
study conducted in routine clinical practices in 28 countries. In China, there were
8,578 T2DMpatients recruited from 131 hospitals into the BIAsp30 treatment group
(starting insulin with or switching to BIAsp30 at baseline based on physicians’
clinical judgments). HRQoLwas assessed at baseline and 24weeks by the validated
EQ-5D questionnaire (five dimensions and visual analogue scale (VAS)). Descriptive
statistics, paired t-test, and chi-square were conducted for the analyses. RESULTS:
Themean age of patients (SD) was 54.914.4 years. 57% were male. The reported
HRQoL as measured by VAS score (on a scale of 0-100) increased by 6.2 from 75.8 to
82.0 for the overall cohort (p0.001). For insulin naïve patients, starting insulin
with BIAsp30 was associated with a 6.1 increase in VAS score from 75.9 to 82.0
(p0.001). Similarly, for insulin experienced patients, switching to BIAsp30 was
associated with a 6.7 increase in VAS score from 75.3 to 82.0 (p0.001). For the
overall cohort in the five dimensions of EQ-5D, the percentage of patients reported
no problems in walking increased from 88.4% to 91.4% (p0.0001) after 24 weeks.
Similarly, the percentage of patients reported no pain or discomfort increased from
77.3% to 82.8% (p0.0001), reported not anxious or depressed increased from 74.2%
to 77.1% (p0.001). The percentage of patients reported no problems in self-care
and usual activity only slightly reduced (-0.2%, -0.5%, respectively) with no statis-
tical significance. CONCLUSIONS: Starting insulin with, or switching to, BIAsp30
were associated with significant HRQoL improvement in Chinese T2DM subjects of
the A1chieve study.
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VALIDATION OF THE PROBLEM AREAS IN DIABETES QUESTIONNAIRE AMONG
PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SINGAPORE: A PILOT STUDY
Rajaram R
National University of Singapore, Singapore, singapore, Singapore
Psychological distress often occurs in patients with diabetes, resulting in poorer
therapeutic outcomes. The Problem Areas in Diabetes (PAID) questionnaire covers
frequently reported diabetes related emotional problems. Utilizing PAID to identify
distressed diabetic patients would be beneficial. OBJECTIVES: PAID was originally
developed for the American population. Cross-cultural differences in health per-
ceptions are well documented; thus it is necessary to verify the validity and reli-
ability of PAID in Singapore. Design: Cross-sectional study. PARTICIPANTS: Pa-
tients with Type 2 diabetes, 21-65 years old, English-speaking, without obvious
cognitive impairment and visited the Diabetes Clinic at National University
Hospital.METHODS: Validity of the scale was evaluated by factor analysis, known
group (defined by socio-demographics and clinical variables), convergent/diver-
gent and concurrent validity. Reliability (internal consistency) was evaluated by
Cronbach’s alpha. RESULTS: Exploratory factor analysis revealed three factors. All
items loaded onto one factor (distress related problems). A few items loaded onto
multiple factors. PAID scores were significantly higher in patients with HbA1c 7.5%
(p0.02) and living in HDB 5-room or smaller flats (p0.01), supporting known
group validity. Other hypothesized known group differences were not observed.
PAID correlated significantly with Kessler10 (K10) and World Health Organization
Quality of Life (WHOQOL-BREF), thus demonstrating convergent and concurrent
validity. PAID correlatedweaklywithWHOQOL-BREF’s physical domain, thus dem-
onstrating divergent validity. Internal consistency was high (Cronbach’s
alpha0.96). CONCLUSIONS: PAID is a valid and reliable scale to evaluate diabetes-
related emotional distress in the Singaporean Type 2 diabetes population. Further
evidence on known group validity needs to be accumulated in future studies.
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GLYCEMIC CONTROL AND QUALITY OF LIFE FOR PATIENTS WITH TYPE 2
DIABETES MELLITUS IN CHINA
Xie K1, Wu J1, Xie J2, Zheng Y1, Yang HY3, Wu EQ2
1Tianjin University, Tianjin, China, 2Analysis Group, Inc., Boston, MA, USA, 3Tulane University,
New Orleans, LA, USA
OBJECTIVES: To examine the association between glycemic control and quality of
life (QoL) among patientswith type 2 diabetesmellitus (T2DM) in China.METHODS:
Data were obtained from a cross-sectional survey of T2DM patients in outpatient
settings from October to December 2011 in Beijing and Tianjin. Eligible patients
were 18 years, had a diagnosis of T2DM 1 year and received 1 year anti-
diabetic treatment at the time of survey. EQ-5D index score and visual analog scale
(VAS) score were calculated for all T2DM patients and compared between sub-
groups defined by fasting blood glucose control (FBG8 mmol/L) and 2-hour post-
prandial glucose control (2h-BG10mmol/L).Multivariate linear regressionmodels
were applied to assess the associations between glucose control and patient QoL,
adjusting for age, gender, BMI, weight gain, education and life style (including
smoking, drinking and exercise). RESULTS: A total of 500 patients with T2DMwere
included in the analysis with 54.6% female, mean age of 63.2 years and mean
disease duration of 11.5 years. Among them, 64.6% reported FBG8mmol/L and
45.6% reported 2h-BG10mmol/L based on the last test in the past 2 weeks. Mean
EQ-5D and VAS scores for all patients were 0.78 and 68.25, respectively. Compared
with patients without FBG control, patients with FBG control had significantly
higher EQ-5D (0.80 vs. 0.75, P0.005) and VAS scores (69.40 vs. 66.16, P0.017).
Similarly, patients with 2h-BG control had significantly higher scores than those
without 2h-BG control (0.82 vs. 0.75 for EQ-5D; 71.82 vs. 65.26 for VAS, both
P0.001). The regression analysis showed that 2h-BG control, but not FBG control,
was significantly associatedwith higher EQ-5D (P0.035) and VAS scores (P0.000).
Older age, less education, weight gain and less exercise were also significantly
associated with lower QoL. CONCLUSIONS: Better glycemic control at 2-hour post-
prandial is associated with improved QoL in patients with T2DM.
INFECTION - Clinical Outcomes Studies
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EFFICACY AND SAFETY OF TENOFOVIR AS COMPARED WITH ALTERNATIVE
TREATMENT OPTIONS FOR NAIVE CHRONIC HEPATITIS B – A SYSTEMATIC
REVIEW AND MIXED TREATMENT COMPARISON
Skarzynska-Duk J1, Stozek A1, Mucha A1, Mierzejewski P2, Kazmierski M2, Wladysiuk M1,
Plisko R1, Rys P1
1HTA Consulting, Krakow, Poland, 2Gilead Sciences Poland Sp. z o.o., Warszawa, Poland
OBJECTIVES: To assess efficacy and safety of tenofovir (TDF) as compared with
other nucleot(s)ide analogues (NAs) and peginterferon alpha 2a (PegIFN2a) for
naive chronic hepatitis B.METHODS: Comparison was based on randomized con-
trolled trials (RCTs) identified bymeans of systematic review, carried out according
to the Cochrane Collaboration guidelines. Studies met the inclusion criteria if they
directly compared at least two of the following interventions: TDF, PegIFN2a ETV,
ADV, LAMor placebo. Themost importantmedical databases (MEDLINE, CENTRAL,
EMBASE) were searched until February 2012. Two reviewers independently se-
lected trials, assessed their quality and extracted data. Mixed treatment compari-
son (MTC) was performed using WinBugs software. Subgroup analysis was per-
formed according hepatitis B antigen e status. RESULTS:We identified 20 relevant
studies. The results of MTC showed that in app. one year of follow up TDF signifi-
cantly increased the odds of HBV DNA clearance when compared with PegIFN2a
(OR 66.22 [5.98; 733.54]); ETV (OR 8.45 [1.12; 63.98]); ADV (OR 13.04 [3.62; 46.94])
and LAM (OR 41.72 [5.27; 330.54]). TDF was superior than PegIFN2a with respect
to ALT normalization (OR  3.07 [1.04; 9.09]) but did not differ significantly from
other NAs. Percentage of patients with any adverse events was significantly lower
in TDF group when compared with PegIFN2a (OR  0.19 [0.07; 0.48]), while no
differenceswere found between TDF and placebo aswell as other NAswith respect
to the safety profile. The rates of ALT flares were similar in all treatments arms. In
contrast to other NAs there were no resistance to TDF through five years.
CONCLUSIONS: TDF demonstrated the highest efficacy with respect to the reduc-
tion of viral load in treatment naïve patients with chronic HBV and maintained a
very good safety profile.
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ASSESSING THE DIAGNOSTIC PERFORMANCE OF HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 (HIV-1) TROPISM TESTING METHODS: A SYSTEMATIC REVIEW OF
GENOTYPIC SEQUENCING OF THE THIRD HYPERVARIABLE (V3) LOOP AND
ENHANCED-SENSITIVITY PHENOTYPIC ASSAY TECHNOLOGY
Needham MO, Paech D, Norris S, Campbell S
OptumInsight, Sydney, NSW, Australia
OBJECTIVES: To evaluate the relative diagnostic performance of genotypic se-
quencing and enhanced-sensitivity phenotypic testing methods for: i) identifying
the tropism of HIV-1 infected patients, and ii) predicting virological response to
CCR5-antagonist therapy. METHODS: A systematic review of the literature (via
EMBASE and Medline databases) initially identified 359 publications. Based on a
priori defined eligibility criteria, five studies were included in the final analysis.
RESULTS: Four of the five studies assessed the diagnostic performance of genotypic
testing in identifying viral tropism, with the enhanced-sensitivity Trofile assay
(ESTA) as the reference standard. Using the geno2pheno bioinformatic algorithm,
genotypic testing maintained a high concordance with ESTA (range: 70.6%-85.3%).
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